Skip to main content

Advertisement

Table 4 Correlation between prognostic factors and androgen concentrations in blood and prostate tissue*

From: High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients

  Gleason score Clinical stage % positive cores
Parameter ≥8 ≤7 p value HR 95% CI ≥IV ≤III p value HR 95% CI ≥30% <30% p value HR 95% CI
No. of patients 63 130     27 166     50 143    
Median age (SD), years 73.0 (7.1) 69.5 (7.2) 0.076 1.050 0.995–1.108 75.0 (7.3) 70.0 (7.2) 0.255 1.049 0.966–1.138 73.0 (7.4) 70.0 (7.1) 0.120 1.052 0.987–1.121
Median serum PSA (95% CI), ng/mL 32.1 (69.2-216.2) 8.76 (12.3-20.2) 0.001 1.022 1.009–1.036 55.9 (113.4-435.8) 9.68 (16.5-27.9) 0.010 1.009 1.002–1.017 52.8 (83.6-262.0) 8.61 (9.6-24.8) 0.005 1.017 1.005–1.030
Median prostate volume, mL 27.0 (28.5-40.0) 27.9 (28.8-34.0) 0.387 0.991 0.970–1.012 33.2 (31.7-55.1) 27.5 (28.3-32.8) 0.057 1.024 0.999–1.049 28.4 (29.3-41.0) 27.6 (28.6-34.1) 0.164 0.982 0.957–1.007
Median concentration of T (95% CI) (blood) (/1000), pg/mL 3.11 (2.90-3.62) 3.64 (3.67-4.14) 0.012 0.706 0.538–0.926 3.21 (2.56-4.06) 3.61 (3.56-3.96) 0.354 0.839 0.579–1.216 3.12 (2.84-3.74) 3.66 (3.62-4.06) 0.113 0.78 0.575–1.060
Median concentration of DHT (95% CI) (tissue), pg/mg 5.31 (6.15-10.27) 7.31 (9.26-13.02) 0.222 0.974 0.935–1.016 4.68 (3.94-11.16) 7.28 (9.04-12.18) 0.756 0.992 0.942–1.044 5.26 (4.86-7.32) 7.58 (9.77-13.46) 0.003 0.878 0.806–0.956
Median concentration of T (95% CI) (tissue), pg/mg 0.90 (1.20-2.23) 0.46 (0.68-1.09) 0.041 1.388 1.013–1.900 2.03 (1.74-3.84) 0.50 (0.72-1.06) 0.002 1.713 1.227–2.391 1.03 (1.42-2.70) 0.47 (0.67-1.02) 0.001 2.432 1.425–4.148
  1. *Multivariate analysis by logistic regression. SD: Standard deviation; HR: Hazard ratio; CI: Confidence interval.